Immunoablation Treatment with Support of HaematopoieticStem Cells in Refractory Forms of Multiple Sclerosis

Czech version

Authors: T. Kozák; E. Havrdová; J. Piťha; E. Gregora; R. Pytlík; J. Maaloufová; M. Greplová; D. Kraftová; P. Kobylka; Š. Vodvářková
Authors‘ workplace: Oddělení klinické hematologie FN KV, Praha, přednosta MUDr. L. Rosa, CSc. Neurologická klinika VFN, Praha, přednostka prof. MUDr. S. Nevšímalová, DrSc. Neurologická klinika FN KV, Praha, přednosta doc. MUDr. P. Kalvach, CSc. Transfuzní oddělení FN KV, Pra
Published in: Prakt. Lék. 2000; (4): 187-190
Category:

Overview

Immunosuppression and immunomodulation is a standard therapeutic strategy in the management of multiple sclerosis (MS). Advanced and rapidly progressive forms which do not respondto conventional type of therapy have a poor prognosis. Only 30% of patients confined toa wheelchair survive 10 years. High dose immunosuppressive therapy, immunoablation, withhaematopoietic stem cell support may be considered to arrest further progression of intractableforms of the disease. Here we present the results of this strategy in 10 patients. Toxicity of theprocedure was manageable. The primary goal was to stop progression. However, one patientimproved significantly, 3 patients improved slightly their EDSS, 6 patients improved theirSNRS. Improvement can occur several months after the procedure. One patient is progressingat her previous rate. In most patients, the dose of oral corticosteroids decreased significantly,further improving the quality of life.

Key words:
multiple sclerosis - treatment - immunoablation.

Full text is not available online.

If interested in a scan of this journal, contact NTO ČLS JEP.